Literature DB >> 24666377

Gonadal function in males with autoimmune Addison's disease and autoantibodies to steroidogenic enzymes.

M Dalla Costa1, G Bonanni, S Masiero, D Faggian, S Chen, J Furmaniak, B Rees Smith, R Perniola, G Radetti, S Garelli, S Chiarelli, M P Albergoni, M Plebani, C Betterle.   

Abstract

Steroidogenic enzyme autoantibodies (SEAbs) are frequently present and are markers of autoimmune premature ovarian failure (POF) in females with autoimmune Addison's disease (AAD). The prevalence and significance of SEAbs in males with AAD have not yet been defined. We studied the prevalence of SEAbs in a large cohort of males with AAD and assessed the relationship between SEAbs positivity and testicular function. A total of 154 males with AAD (mean age 34 years) were studied. SEAbs included autoantibodies to steroid-producing cells (StCA), detected by immunofluorescence, and steroid 17α-hydroxylase (17α-OHAbs) and side chain cleavage enzyme (SCCAbs) measured by immunoprecipitation assays. Gonadal function was evaluated by measuring follicle-stimulating hormone (FSH), luteinizing hormone (LH), total testosterone (TT), sex hormone-binding globulin (SHGB), anti-müllerian hormone (AMH) and inhibin-B (I-B). Twenty-six males, 10 SEAbs((+)) and 16 SEAbs((-)), were followed-up for a mean period of 7·6 years to assess the behaviour of SEAbs and testicular function. SEAbs were found in 24·7% of males with AAD, with the highest frequency in patients with autoimmune polyendocrine syndrome type 1 (APS-1). The levels of reproductive hormones in 30 SEAbs((+)) males were in the normal range according to age and were not significantly different compared to 55 SEAbs((-)) males (P > 0·05). During follow-up, both SEAbs((+)) and SEAbs((-)) patients maintained normal testicular function. SEAbs were found with high frequency in males with AAD; however, they were not associated with testicular failure. This study suggests that the diagnostic value of SEAbs in males with AAD differs compared to females, and this may be related to the immunoprivileged status of the testis.
© 2014 British Society for Immunology.

Entities:  

Keywords:  Addison's disease; autoantibodies to steroidogenic enzymes; autoimmune polyendocrine syndromes; gonadal function; testis autoimmunity

Mesh:

Substances:

Year:  2014        PMID: 24666377      PMCID: PMC4008981          DOI: 10.1111/cei.12303

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  21 in total

1.  Premature ovarian failure in patients with autoimmune Addison's disease: clinical, genetic, and immunological evaluation.

Authors:  G Reato; L Morlin; S Chen; J Furmaniak; B Rees Smith; S Masiero; M P Albergoni; S Cervato; R Zanchetta; C Betterle
Journal:  J Clin Endocrinol Metab       Date:  2011-06-15       Impact factor: 5.958

2.  Immunological features of idiopathic Addison's disease: an antibody to cells producing steroid hormones.

Authors:  J R Anderson; R B Goudie; K Gray; D A Stuart-Smith
Journal:  Clin Exp Immunol       Date:  1968-02       Impact factor: 4.330

3.  Immunofluorescence studies on autoantibodies to steroid-producing cells, and to germline cells in endocrine disease and infertility.

Authors:  F Sotsiou; G F Bottazzo; D Doniach
Journal:  Clin Exp Immunol       Date:  1980-01       Impact factor: 4.330

4.  Progressive decline of residual follicle pool after clinical diagnosis of autoimmune ovarian insufficiency.

Authors:  Alberto Falorni; Annalisa Brozzetti; Maria Chiara Aglietti; Raffaella Esposito; Viviana Minarelli; Silvia Morelli; Emilia Sbroma Tomaro; Stefania Marzotti
Journal:  Clin Endocrinol (Oxf)       Date:  2012-09       Impact factor: 3.478

Review 5.  Testicular autoimmunity.

Authors:  Patricia Jacobo; Vanesa Anabella Guazzone; María Susana Theas; Livia Lustig
Journal:  Autoimmun Rev       Date:  2010-10-14       Impact factor: 9.754

6.  The cytotoxic effect of serum from patients with Addison's disease and autoimmune ovarian failure on human granulosa cells in culture.

Authors:  K P McNatty; R V Short; E W Barnes; W J Irvine
Journal:  Clin Exp Immunol       Date:  1975-12       Impact factor: 4.330

Review 7.  Male hypogonadism: an extended classification based on a developmental, endocrine physiology-based approach.

Authors:  R A Rey; R P Grinspon; S Gottlieb; T Pasqualini; P Knoblovits; S Aszpis; N Pacenza; J Stewart Usher; I Bergadá; S M Campo
Journal:  Andrology       Date:  2012-10-09       Impact factor: 3.842

8.  Adrenal and steroidal cell antibodies in patients with autoimmune polyglandular disease type I and risk of adrenocortical and ovarian failure.

Authors:  P Ahonen; A Miettinen; J Perheentupa
Journal:  J Clin Endocrinol Metab       Date:  1987-03       Impact factor: 5.958

Review 9.  Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction.

Authors:  Corrado Betterle; Chiara Dal Pra; Franco Mantero; Renato Zanchetta
Journal:  Endocr Rev       Date:  2002-06       Impact factor: 19.871

10.  Isolated gonadotrope failure in the polyglandular autoimmune syndrome.

Authors:  A L Barkan; R P Kelch; J C Marshall
Journal:  N Engl J Med       Date:  1985-06-13       Impact factor: 91.245

View more
  3 in total

Review 1.  Epidemiology of Male Hypogonadism.

Authors:  Arthi Thirumalai; Bradley D Anawalt
Journal:  Endocrinol Metab Clin North Am       Date:  2022-02-08       Impact factor: 4.748

Review 2.  Autoimmune Addison's Disease as Part of the Autoimmune Polyglandular Syndrome Type 1: Historical Overview and Current Evidence.

Authors:  Roberto Perniola; Alessandra Fierabracci; Alberto Falorni
Journal:  Front Immunol       Date:  2021-02-26       Impact factor: 7.561

3.  Autoimmune polyendocrine syndrome type 1: an Italian survey on 158 patients.

Authors:  S Garelli; M Dalla Costa; C Sabbadin; S Barollo; B Rubin; R Scarpa; S Masiero; A Fierabracci; C Bizzarri; A Crinò; M Cappa; M Valenzise; A Meloni; A M De Bellis; C Giordano; F Presotto; R Perniola; D Capalbo; M C Salerno; A Stigliano; G Radetti; V Camozzi; N A Greggio; F Bogazzi; I Chiodini; U Pagotto; S K Black; S Chen; B Rees Smith; J Furmaniak; G Weber; F Pigliaru; L De Sanctis; C Scaroni; C Betterle
Journal:  J Endocrinol Invest       Date:  2021-05-18       Impact factor: 4.256

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.